|
| Risk factors | Hazard Ratio (95% CI) | |
|
| Demographics |
| Age at LT (per yr) | 1.5 (0.8–2.8) | 0.27 |
| Sex (M : F) | 1.4 (1.1–1.9) | 0.02 |
| Smoking at time of LT (Yes : No) | 1.9 (0.5–5.0) | 0.23 |
|
| Transplant-related variables |
| Allograft failure (Y : N) | 1.1 (0.8–1.4) | 0.72 |
| Recurrence of PSC (Y : N) | 0.8 (0.6–1.1) | 0.12 |
| Steroid-resistant rejection | 1.3 (0.7–2.2) | 0.22 |
| Chronic rejection | 1.1 (0.8–1.9) | 0.77 |
|
| Immunosuppression |
| Tacrolimus-based immunosuppression (v. Cyclosporine-based) | 2.1 (1.5–3.1) | <0.01 |
| Mycophenolate mofetil use after LT (Y : N) | 2.4 (1.6–3.5) | <0.01 |
| Azathioprine use after LT (Y : N) | 1.1 (0.7–1.6) | 0.53 |
| Prolonged prednisone (>6 months) (Y : N) | 0.3 (0.1–1.5) | 0.13 |
|
| IBD-related variables |
| Pre-LT IBD | 0.9 (0.6–1.3) | 0.62 |
|
